• Source: ADBICA

ADBICA (also known as ADB-PICA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, like SDB-001 and STS-135. The stereochemistry of the tert-butyl side-chain in the product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers. ADBICA is a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 0.69 nM and 1.8 nM respectively.




Legal Status


As of October 2015 ADBICA is a controlled substance in China.




See also






References

Kata Kunci Pencarian:

• ADBICA
• 5F-ADBICA
• ADB-FUBINACA
• 5F-ADB-PINACA
• ADB-PINACA
• 5F-AB-PINACA
• Cannabis (drug)
• List of designer drugs
• AB-FUBINACA
• Ketamine